Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Supplement—October 2025
SUPPLEMENT ISSUE
Supplement
Persistence of Symptoms among Commercially Insured Patients with Coccidioidomycosis, United States, 2017–2023
, Samantha L. Williams, Kaitlin Benedict, Dallas J. Smith, George R. Thompson, and Mitsuru Toda
Table 1
Demographic characteristics, underlying conditions, and coccidioidomycosis type among 2,640 commercially insured patients with coccidioidomycosis, United States, July 2017‒January 2023*
| Characteristic | No. (%) |
|---|---|
| Sex | |
| M | 1,363 (52) |
| F |
1,277 (48) |
| Median age, y (IQR) |
51.0 (39.0–60.0) |
| Age group, y | |
| <18 | 123 (5) |
| 18‒44 | 803 (30) |
| 45‒64 | 1,326 (50) |
| >65 |
388 (15) |
| US Census region of primary beneficiary's residence† | |
| Northeast | 80 (3) |
| Midwest | 219 (8) |
| South | 266 (10) |
| West |
2,047 (78) |
| Rural status‡ | |
| Rural | 123 (5) |
| Nonrural |
2,304 (95) |
| Underlying conditions | 898 (66) |
| Asthma or COPD | 633 (24) |
| Diabetes | 426 (18) |
| Hypertension | 850 (35) |
| Immunosuppression§ |
971 (40) |
| Coccidioidomycosis type on index date | |
| Pulmonary | 1,336 (51) |
| Cutaneous | 52 (2) |
| Disseminated | 118 (4) |
| Other or unspecified | 1,277 (48) |
*Values are no. (%) except as indicated. COPD, chronic obstructive pulmonary disease; IQR, interquartile range. †Regions were derived from US Census regions (https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf). ‡Rural versus nonrural status were based on US Census metropolitan statistical area designation. §Immunosuppression related to autoimmune disease, cancer, HIV, solid organ transplant, immunosuppressive medication, or a combination of those factors.
1Current affiliation: The Carter Center, Atlanta, Georgia, USA